Mazzucconi M G, Mandelli F, Mariani G, Briët E, Veltkamp J J
Br J Haematol. 1977 May;36(1):127-35. doi: 10.1111/j.1365-2141.1977.tb05762.x.
Nine patients with severe factor-VII deficiency, belonging to seven pedigrees were studied for the presence of factor-VII-CRM with an inhibitor neutralization assay. The antibody, raised in rabbits, did not precipitate the antigen and could only be used in a fluid phase assay to measure the capacity of plasma to neutralize inhibitory activity directed against factor-VII activity. In one of these nine patients normal amounts of factor-VII-CRM could be demonstrated. The CRM + patient did not show a clinical picture at variance with that of the CRM-patients. The investigation into this CRM+ pedigree revealed heterozygosity in nine out of 12 persons when using the ratio between biological factor-VII activity and factor-VII-CRM as the criterion.
对来自7个家系的9名重度因子VII缺乏症患者进行了研究，采用抑制剂中和试验检测因子VII交叉反应物质（CRM）的存在情况。在兔体内产生的该抗体不能使抗原沉淀，仅能用于液相试验，以测定血浆中和针对因子VII活性的抑制活性的能力。在这9名患者中，有1名可检测到正常量的因子VII-CRM。CRM阳性患者的临床表现与CRM阴性患者并无差异。对这个CRM阳性家系的调查显示，以生物学因子VII活性与因子VII-CRM的比值为标准时，12人中9人为杂合子。
